Anne Wojcicki, co-founder of 23andMe, a DNA testing company, has won back control of the firm through a bankruptcy court sale.

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s nonprofit acquires 23andMe.

In a landmark shift for consumer genomics, Anne Wojcicki, the co-founder and former CEO of 23andMe, has announced the acquisition of the embattled DNA testing giant by her newly formed nonprofit ...

A bankruptcy judge approved the sale of 23andMe's assets and business operations to a nonprofit led by 23andMe's co-founder and former chief executive, Anne Wojcicki.

Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

Scion Asset Management, founded by Michael Burry of "Big Short" fame, started new positions in consumer and healthcare names including lululemon athletica (LULU ...

Following the sale of the direct-to-consumer genetic testing company 23andMe, the Utah Attorney General’s Office is issuing a ...

Following the sale of the direct-to-consumer genetic testing company 23andMe, the Utah Attorney General’s Office is issuing a consumer advisory reminding former customers of ways to protect ...

Shares of Regeneron Pharmaceuticals Inc. REGN slipped 1.36% to $542.52 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0. ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the most profitable biotech stocks to invest in now. Canaccord updated estimates on Regeneron Pharmaceuticals, Inc.